Month: March 2022

SHANGHAI, China, March 29, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today reported financial results for the year ended December 31, 2021. “2021 was a remarkable year for Clover. We announced positive Phase 2/3 data for our COVID-19 vaccine candidate, raised significant capital including completing an IPO, and expanded our headcount to establish global development capabilities and prepare for commercial launch. We carried this momentum into the first quarter of 2022 by announcing exciting preliminary booster data against Omicron, results that drive us closer to achieving our vision of empowering humanity with a healthier future through transformative science,” said Joshua Liang, Chief...

F2021 Revenue More than Doubles to $8.15M; F2022 Revenue Guidance Exceeding $10M TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — Clear Blue Technologies International Inc. (“Clear Blue” or “the Company”) (TSXV: CBLU), today announces its financial results for the year ended December 31, 2021, F2022 guidance and outlook, and the details for its quarterly conference call, which will take place on Tuesday, March 29, 2022, at 11 am Eastern (details below). All figures are in Canadian dollars unless stated otherwise. F2021 Financial Results2021 revenue was a record $8,148,659, a 103% increase over 2020; Gross profit was $2,255,460 (or 28%) a 78% increase from the previous comparative period ($1,266,999 or 31%); Non-IFRS Adjusted EBITDA for 2021 was $(2,563,334) as compared to $(3,590,285) for 2020; Telecom Vertical revenues grew by 182%...

Unveils Bioleum™ Breakthrough; A Carbon Neutral Crude Oil Capable of Replacing Fossil Crude VIRGINIA CITY, Nev., March 29, 2022 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced its 2021 results, summary of transactions completed in 2021, and our new business outlook. Selected Strategic HighlightsApproved a new strategy with a mission of enabling systemic decarbonization and a vision of a net zero carbon world. Acquired Comstock Innovations, formerly Plain Sight Innovations, with a portfolio of intellectual property that contributes to global decarbonization by efficiently converting massive supplies of unused and under-utilized woody-biomass resources into cellulosic ethanol, renewable diesel, sustainable aviation fuel, and other drop-in fuels. Acquired LINICO Corporation and...

Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Developed IO Candidate Anti-KLRG1 (PYX-102) Cash Runway Sufficient for Multiple Milestones Through Third Quarter 2024 Company to Host Conference Call and Webcast Today at 8:00 a.m. ET CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today provided a corporate and financial update and reported financial results for the full year ended December 31, 2021. “We have had a highly productive start to 2022, advancing our lead programs toward first-in-human clinical trials while executing our strategy of identifying the...

– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones – – Ongoing Progress in Clinical Programs with Two Phase 2 Studies of Two Doses of IGM-2323, 100 mg and 300 mg, in Patients with DLBCL and FL Initiated – – Company to Host Conference Call and Webcast Today at 8:00 a.m. EST – MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent developments. “IGM continues to make progress in...

Annual retail sales increased 22.7% to $1.3 billionAnnual eCommerce sales increased 171.3% to a record $71.3 millionAnnual credit spread of 1,170 basis points, helps drive record annual credit segment profitabilityAnnual GAAP earnings increased to a record $3.61 per diluted shareRepurchased 20% of the Company’s outstanding shares THE WOODLANDS, Texas, March 29, 2022 (GLOBE NEWSWIRE) — Conn’s, Inc. (NASDAQ: CONN) (“Conn’s” or the “Company”), a specialty retailer of home goods, including furniture, appliances and consumer electronics, with a mission to elevate home life to home love, today announced its financial results for the quarter and year ended January 31, 2022.  “Total retail sales increased 22.7% in fiscal year 2022 despite ongoing industry wide supply chain challenges and the emergence of the COVID-19 Omicron variant during...

Annual Gross Margin Reached 63.4% Special Conditions for the EH216-S Type Certification Adopted by the CAAC Operational Trial Flights under the 100 Air Mobility Routes Initiative Expanded to Over 4,000 at 9 Spots in China Sizable AAV Pre-orders and Growing UAM Market Demand from More Asian CountriesGUANGZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Financial and Operational Highlights for the Fourth Quarter 2021Total revenues were RMB8.7 million (US$1.4 million), compared with RMB13.0 million in the third quarter of 2021.Gross margin was 60.1%, representing a continued...